Latest news
Nurix Starts Phase 3 Trial of Bexobrutideg Against Pirtobrutinib in CLL - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 06:33:26 GMTNurix Phase 3 Trial Tests Bexobrutideg Against CLL Standard of Care - Stock TitanStock Titan · Tue, 04 Aug 2026 05:03:02 GMTNurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma - finance.yahoo.comfinance.yahoo.com · Tue, 04 Aug 2026 05:00:00 GMT